| XTL BIOPHARMA. ADR 100 |
| USA |
| Gesundheit |
| US98386D3070 / A2DK34 |
| H2K2 (Frankfurt) / XTLB (NASDAQ) |
| FRA:H2K2, ETR:H2K2, H2K2:GR, NASDAQ:XTLB |
| - |
| http://www.xtlbio.com |
|
XTL Biopharmaceuticals Ltd. is a biotechnology company engaged in the development and commercialization of pharmaceutical products for the treatment of unmet medical needs. The company's primary focus is on the development of therapeutics for deliver..
>Volltext.. |
| 5.5 Mio. EUR |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| XTL BIOPHARMACEUTICALS, XTL BIO, XTL BIOPHARMA |
| 05.04.26 |
|